NEW YORK – Spatial proteomics firm Syncell of Taiwan said Thursday that it has closed a $15 million Series A funding round.
The Taipei-based company said it will use the funds to expand and accelerate commercialization of its Microscoop spatial proteomics platform.
The round was led by Taiwania Capital, with participation from new and existing investors, and brings Syncell's total raised to $30 million.
The Microscoop system allows users to target specific regions of interest within a cell or tissue sample for protein extraction and analysis via readout methods like mass spectrometry. The company recently signed a memorandum of understanding with Thermo Fisher Scientific covering the use of that firm's mass spectrometers and workflows.
"Syncell’s spatial opto-proteomics platform enables us to uncover the proteins present in disease-associated aggregates within human postmortem brain tissue," Wilfried Rossoll, associate professor of neuroscience at the Mayo Clinic, said in a statement. "This technology allows us to identify potential biomarkers for future diagnostics or therapeutic targets in an unbiased manner — achievements not possible with other spatial biology methods. I see immense potential in subcellular protein profiling and spatial proteomics to discover proteins in locations inaccessible to other technologies."
"The Series A investment will power the next phase of our growth, enabling us to build out a full commercial team and scale up our operations to support the growing demand for our technology for spatial biologists and cell biologists, giving them the ability to accurately discover new protein components from targeted regions of interest," Jung-Chi Liao, Syncell's founder and CEO, said in a statement.